

## REMARKS

### *Claim Amendments*

Claims 194-198, 200, 202-234 and 256-281 are pending. Claims 194 and 256 are amended herein. Support for these amendments can be found throughout the application as filed. *See e.g.*, paragraphs [0166] and [0236]. Claim 256 was previously amended in an Examiner's Amendment. No new matter has been added.

### *Specification Amendments*

Applicants have amended the specification to update the priority information and correct minor, typographical errors. Applicants have also amended paragraph [0047] to change "10b" to "10L," as Figure 10 contains images A-L. Paragraph [0254] was amended to correct an Accession number. No new matter has been added.

### *Drawings*

In the Notice of Allowability mailed on June 28, 2007, the Examiner requests that Applicants submit corrected drawings in accordance with the Notice of Draftsperson's Patent Drawing Review ("Draftsman's Review") and the Examiner's comments. In particular, the Examiner requests that Applicants amend the legend of Figure 9 to only describe Figures 9A and 9B. The Examiner also asserts that while the specification describes Figures 10A, 10B, 16A and 16B, the drawings do not contain these labeled figures.

Applicants respectfully point out that formal drawings were submitted on May 11, 2004 and May 4, 2007 (collectively, "Formal Drawings"). The Draftsman's review, however, is based on drawings filed on December 2, 2003. *See* Draftsman's Review ("The drawing(s) filed (insert date) 12-2-03 are: ... "). Accordingly, it is unclear whether the Formal Drawings have been considered.

Nonetheless, in an effort to expedite issuance, Applicants submit herewith formal drawings and request that these figures be published when the instant application issues. Applicants believe these formal figures are in compliance with 37 C.F.R. § 1.84 and address the Examiner's concerns. Applicants respectfully request that the Examiner notify Applicants if there are any objections to these formal drawings.

***Statement of Substance of Interview Under 37 C.F.R. § 1.133(b)***

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the interview. Applicants appreciate the courtesies extended by Examiner Landsman.

During the interview, Examiner Landsman requested that Applicants amend claims 194 and 256 to recite that the isolated cell expresses a heteromeric receptor that specifically binds to a ligand that specifically binds to an endogenous (wild-type) human T1R2/T1R3 receptor. Applicants have amended claims 194 and 256 herein to reflect this addition.

Applicants representative also indicated that Applicants would identify other co-pending applications that relate to the instant application. Below is a list of these applications:

Application Nos. 10/179,373; 10/725,037; 10/725,076; 10/725,080; 10/725,418; 10/725,472; 10/725,473; 10/725,475; 10/725,488; 10/725,489 and 11/050,804.

### CONCLUSION

Applicants respectfully request entry and consideration of the above amendments and remarks. If the Examiner has any questions relating to this response or the application in general he is respectfully requested to contact the undersigned so that prosecution of this application may be expedited.

It is believed that no fees are required for entry of this response, but should any fees be necessary, the Commissioner is authorized to charge such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

**HUNTON & WILLIAMS, LLP**

Dated: September 24, 2007

By: 

Robin L. Teskin  
Registration No. 35,030

Alexander H. Spiegel  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W. Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

RLT/AHS:ltm